Hello Al,

This HHS OIG report findings may be of interest.

 

Part D Plans Generally Include Drugs Commonly Used by Dual Eligibles: 2019 (OEI-05-19-00220)

Overall, we found that the rate of Part D plan formularies' inclusion of the 196 drugs commonly used by dual eligibles is high, with some variation. On average, Part D plan formularies include 97 percent of the 196 commonly used drugs. In addition, 72 percent of the commonly used drugs are included by all Part D plan formularies. These results are largely unchanged from OIG's findings in our mandated annual report from 2018, as well as from the findings in our reports from 2011 through 2017.

 

 

Leslie Fried, J.D.

Senior Director, Center for Benefits Access

Office: 571.527.3992

xxxxxx@ncoa.org

 

National Council on Aging

Improving the lives of millions of older adults

251 18th Street South, Suite 500

Arlington, VA 22202

ncoa.org | @NCOAging

 

From: HHS OIG <xxxxxx@connect.hhs.gov>
Sent: Tuesday, July 2, 2019 3:26 PM
To: Leslie Fried <xxxxxx@ncoa.org>
Subject: OIG posts three reports and civil monetary penalities and affirmative exclusions

 

This message originated from outside your organization.


The Food and Drug Administration Generally Complied With Federal Requirements for the Preparation and Receipt of Select Agent Shipments

OIG posts three reports and civil monetary penalities and affirmative exclusions. As always, you can use the links provided to go directly to the new material.

------------

Reports

Part D Plans Generally Include Drugs Commonly Used by Dual Eligibles: 2019 (OEI-05-19-00220)

Overall, we found that the rate of Part D plan formularies' inclusion of the 196 drugs commonly used by dual eligibles is high, with some variation. On average, Part D plan formularies include 97 percent of the 196 commonly used drugs. In addition, 72 percent of the commonly used drugs are included by all Part D plan formularies. These results are largely unchanged from OIG's findings in our mandated annual report from 2018, as well as from the findings in our reports from 2011 through 2017.

###

The Food and Drug Administration Generally Complied With Federal Requirements for the Preparation and Receipt of Select Agent Shipments (A-03-16-00354)

Generally, FDA has designed and put in place controls to ensure that select agent shipments are prepared and received in accordance with Federal regulations and related supporting laboratory guidance and instruction. However, 8 of FDA's 11 registered entities' security plans did not include certain procedures for notifying the Federal Select Agent Program (FSAP) if a select agent shipment is not received within 48 hours after the expected delivery time or a select agent shipment receives damage to the extent that a select agent release may have occurred, and none of FDA's registered entities' security plans included certain procedures for notifying FSAP if an authorization for a select agent transfer expires or becomes void before the shipment is completed. In addition, we found that FDA's registered entities did not always maintain required select agent training documentation and did not have sufficient policies to ensure compliance with all new requirements for shipping select agents that have undergone inactivation.

###

Recommendation Followup: Delaware Is Reporting Medicaid Overpayments In Compliance With Federal Requirements (A-03-17-00203)

A previous OIG report found that, in 2009 and 2010, Delaware did not comply with Federal requirements to report all Medicaid overpayment collections. The report had five recommendations that were still unimplemented as of June 30, 2017.

Our objective was to determine whether Delaware implemented recommendations from our previous review and is in compliance with Federal requirements for reporting Medicaid overpayments.

------------

Civil Monetary Penalties and Affirmative Exclusions

------------

 

This email was sent by: U.S. Department of Health and Human Services
200 Independence Avenue, S.W., Washington, DC, 20201 US

Privacy Policy

Update Profile      Manage Subscriptions        Unsubscribe

The information contained in this electronic mail and its attachments is privileged and confidential. It is intended for the use of the addressee and others specifically authorized to receive it. If you are not the intended recipient, you are prohibited from disseminating, distributing or copying this communication. If you have received this e-mail in error, please delete it and notify us by replying to this e-mail immediately.

Disclaimer

The information contained in this communication from the sender is confidential. It is intended solely for use by the recipient and others authorized to receive it. If you are not the recipient, you are hereby notified that any disclosure, copying, distribution or taking action in relation of the contents of this information is strictly prohibited and may be unlawful.

This email has been scanned for viruses and malware, and may have been automatically archived by Mimecast Ltd, an innovator in Software as a Service (SaaS) for business. Providing a safer and more useful place for your human generated data. Specializing in; Security, archiving and compliance. To find out more Click Here.